Search
Neptunus Bio Announces Completion of Phase I Clinical Trial for HW130 Injection
3 week ago /
Read about 0 minute
Author：小编
Neptunus Bio, through its wholly-owned subsidiary, has successfully concluded Phase I clinical trials for its groundbreaking HW130 Injection. The results demonstrate impressive safety and tolerability profiles. HW130 is an innovative anti-tumor medication designed to inhibit tumor blood vessels, mitigate the adverse effects of chemotherapy, and amplify its therapeutic efficacy. While this milestone does not immediately influence the company's current financial performance, Neptunus Bio remains committed to advancing HW130 through further clinical trials.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
